Early aggressive intra-venous pulse cyclophosphamide therapy for interstitial lung disease in a patient with systemic sclerosis. A case report.
Interstitial lung disease is an important cause of mortality and morbidity in patients with systemic sclerosis (SSc). There are currently no recommended guidelines for management of these patients. This is probably due to the rarity of this condition, as well as clinical trials with only a small number of cases. There are published case report and case series along with the two main trials, viz. Scleroderma Lung Study and the Fibrosing Alveolitis Study, but again, there is no consensus on treatment protocols. In this report, we present a case of aggressive interstitial lung disease in a patient with SSc, which improved dramatically on treatment with intra-venous cyclophosphamide and high dose prednisolone therapy.
Peshin
R
R
Department of Rheumatology, Beaumont Hospital, Dublin, Republic of Ireland. rohit_peshin@yahoo.com
O'Neill
L
L
Browne
P
P
O'Connell
P
P
Kearns
G
G
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D012595:Scleroderma, Systemic / Q000150:complications*
D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D011239:Prednisolone